Ranbaxy In Bear Grip As Sales Slip In U.S. After FDA Restrictions
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - India's Ranbaxy, now part of Japanese drug maker Daiichi Sankyo, has witnessed a sharp drop in its market share in the U.S., having lost as much as 40 percent in sales since last August. The drop in prescriptions is at a staggering 50 percent as compared to the company's February 2008 sales data. According to a Deutsche Bank report, this indicates that Ranbaxy will lose further prescriptions and hence revenues
You may also be interested in...
Ranbaxy Reports Corrections At Dewas Plant To FDA; Hopes Import Restrictions Will Be Lifted Soon
CEO Sobti says Ranbaxy has formally asked FDA for a re-inspection of Dewas and "it will be probably a month or a few months."
Ranbaxy Reports Corrections At Dewas Plant To FDA; Hopes Import Restrictions Will Be Lifted Soon
CEO Sobti says Ranbaxy has formally asked FDA for a re-inspection of Dewas and "it will be probably a month or a few months."
Ranbaxy Reports Corrections At Dewas Plant To U.S. FDA; Hopes Import Restrictions Will Be Lifted Soon
MUMBAI - Part of Ranbaxy's troubles with its manufacturing units in India may be coming to an end in the next few months; the company has filed an exhaustive report with the U.S. FDA on corrections made at its manufacturing facilities at Dewas